Literature DB >> 9444314

Dose-dependent effects on the disposition of monomethylarsonic acid and dimethylarsinic acid in the mouse after intravenous administration.

M F Hughes1, E M Kenyon.   

Abstract

The organic arsenicals monomethylarsonic acid (MMA) and dimethylarsinic acid (DMA) are the primary metabolites of inorganic arsenic, a known human carcinogen. The objective of this study was to examine if dose would affect the excretion and terminal tissue disposition of MMA and DMA in the mouse. 14C-MMA (4.84 and 484 mumol/kg) and -DMA (8.04 and 804 mumol/kg) were administered to female mice via the tail vein. The mice were placed in metabolism cages for collection of urine (1, 2, 4, 8, 12, and 24 h) and feces (24 h). The animals were then sacrificed at 24 h and tissues were removed and analyzed for radioactivity. The urine was also analyzed for parent compound and metabolites. Urinary excretion of MMA- and DMA-derived radioactivity predominated over fecal excretion. Dose did not affect the overall urinary excretion of both compounds. However, fecal excretion was significantly lower in the low-dose MMA-treated animals as opposed to in the high-dose group, whereas in the high-dose DMA-treated group excretion was lower than in the low-dose DMA group. The retention of radioactivity was low (< 2% of dose) and the distribution pattern similar for both compounds, with carcass > liver > kidney > lung. The concentration of radioactivity (% dose/g tissue) was greater in kidney than in liver, lung, and blood for both compounds. The distribution and concentration of MMA-derived radioactivity was significantly greater in the liver and lung of the high-dose group. The MMA-treated animals excreted predominantly MMA in urine and lower amounts of DMA (< 10% of the dose). The percentage excreted as DMA was significantly higher in the low-dose MMA group. In the urine of DMA-treated animals, an unstable metabolite and the parent compound were detected. Overall, it appears the dose of organic arsenical administered has a minimal effect on its excretion and terminal tissue disposition in the mouse. The rapid elimination and low retention of MMA and DMA explain in part their low acute toxicity.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9444314     DOI: 10.1080/009841098159385

Source DB:  PubMed          Journal:  J Toxicol Environ Health A        ISSN: 0098-4108


  9 in total

1.  Using mathematical modeling to infer the valence state of arsenicals in tissues: A PBPK model for dimethylarsinic acid (DMAV) and dimethylarsinous acid (DMAIII) in mice.

Authors:  Lydia M Bilinsky; David J Thomas; Jeffrey W Fisher
Journal:  J Theor Biol       Date:  2018-10-26       Impact factor: 2.691

2.  Tissue dosimetry, metabolism and excretion of pentavalent and trivalent monomethylated arsenic in mice after oral administration.

Authors:  Michael F Hughes; Vicenta Devesa; Blakely M Adair; Miroslav Styblo; Elaina M Kenyon; David J Thomas
Journal:  Toxicol Appl Pharmacol       Date:  2005-10-15       Impact factor: 4.219

3.  Individual differences in arsenic metabolism and lung cancer in a case-control study in Cordoba, Argentina.

Authors:  Craig Steinmaus; Yan Yuan; Dave Kalman; Omar A Rey; Christine F Skibola; Dave Dauphine; Anamika Basu; Kristin E Porter; Alan Hubbard; Michael N Bates; Martyn T Smith; Allan H Smith
Journal:  Toxicol Appl Pharmacol       Date:  2010-06-17       Impact factor: 4.219

4.  Identifiability of PBPK models with applications to dimethylarsinic acid exposure.

Authors:  Ramon I Garcia; Joseph G Ibrahim; John F Wambaugh; Elaina M Kenyon; R Woodrow Setzer
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-07-21       Impact factor: 2.745

5.  Disruption of the arsenic (+3 oxidation state) methyltransferase gene in the mouse alters the phenotype for methylation of arsenic and affects distribution and retention of orally administered arsenate.

Authors:  Zuzana Drobna; Hua Naranmandura; Kevin M Kubachka; Brenda C Edwards; Karen Herbin-Davis; Miroslav Styblo; X Chris Le; John T Creed; Noboyu Maeda; Michael F Hughes; David J Thomas
Journal:  Chem Res Toxicol       Date:  2009-10       Impact factor: 3.739

6.  Tissue dosimetry, metabolism and excretion of pentavalent and trivalent dimethylated arsenic in mice after oral administration.

Authors:  Michael F Hughes; Vicenta Devesa; Blakely M Adair; Sean D Conklin; John T Creed; Miroslav Styblo; Elaina M Kenyon; David J Thomas
Journal:  Toxicol Appl Pharmacol       Date:  2007-10-22       Impact factor: 4.219

7.  Dietary intake and arsenic methylation in a U.S. population.

Authors:  Craig Steinmaus; Kenichi Carrigan; Dave Kalman; Raja Atallah; Yan Yuan; Allan H Smith
Journal:  Environ Health Perspect       Date:  2005-09       Impact factor: 9.031

8.  Toxicity Screening of Single Dose of Inorganic and Organic Arsenics on Hematological and Serum Biochemical Parameters in Male Cynomolgus Monkeys.

Authors:  Choong-Yong Kim; Kang-Hyun Han; Jeong-Doo Heo; EuiSik Han; YoungNa Yum; Jin-Young Lee; KyungSu Park; Ruth Im; Seong-Jin Choi; Jung-Duck Park
Journal:  Toxicol Res       Date:  2008-09-01

9.  Metabolism of low-dose inorganic arsenic in a central European population: influence of sex and genetic polymorphisms.

Authors:  Anna-Lena Lindberg; Rajiv Kumar; Walter Goessler; Ranjit Thirumaran; Eugen Gurzau; Kvetoslava Koppova; Peter Rudnai; Giovanni Leonardi; Tony Fletcher; Marie Vahter
Journal:  Environ Health Perspect       Date:  2007-07       Impact factor: 9.031

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.